Valeant launches $1.25B private debt offering

|By:, SA News Editor

Valeant Pharmaceuticals (NYSE:VRX) commences a private offering of $1.25B aggregate principal amount of unsecured senior notes due 2026.

Net proceeds will help fund the repurchase of $1.25B of outstanding debt, including its 6.375% Senior Notes due 2020, 5.375% Senior Notes due 2020 and up to $100M of its 6.750% Senior Notes due 2021.

Subscribe for full text news in your inbox